7:30 am – 8 am: Registration
8 am – 12:15 pm: Training
12:15 pm – 12:45 pm: Community behavioral health partners networking & lunch
The PCSS Half-and-Half Medication Assisted Treatment (MAT) waiver training course provides an overview of the FDA-approved medication buprenorphine prescribed for the treatment of opioid use disorder (OUD). The course meets the required 8-hour training to prescribe buprenorphine for the treatment of OUD. The course trainer will conduct an overview of prevention, identification, and treatment of substance use disorders emphasizing OUD.
The buprenorphine waiver 8-hour training is offered in a ‘half- and-half’ format – 4 hours of in-person training followed up by 4 hours of online training through PCSS-MAT. Upon completion of the required training, providers will meet the requirement of the DATA 2000 to apply for a waiver to prescribe buprenorphine for opioid-dependent patients.
Physicians are required to complete the standardized buprenorphine waiver 8-hour training.
Nurse Practitioners (NPs) and Physician Assistants (PAs) are required to complete the standardized buprenorphine waiver 8-hour training as well as an additional 16 hours of online training as established by the Comprehensive Addiction and Recovery Act (CARA) which can be found here:
At the conclusion of this activity participants should be able to:
- Review addiction treatment in office-based practices
- Discuss the pharmacological treatments of opioid use disorder
- Determine what medical record documentation must be followed
- Discuss the process of buprenorphine induction as well as stabilization and maintenance techniques
- Describe how to take a patient history and evaluation
- Review safety concerns and drug interactions
Eric Weintraub, MD
Maryland Addiction Consultation Service (MACS) Consultant
Associate Professor of Psychiatry, University of Maryland, School of Medicine
Division Head, Alcohol & Drug Abuse; Acting Division Head, Adult Psychiatry, University of Maryland, School of Medicine
Director Division of Alcohol and Drug Abuse Co-Director of Adult Psychiatry, UMMC
Tracy Sommer, LMSW
MACS Behavioral Health Consultant
Application for CME credit has been filed with the American Academy of Family Physicians (AAFP) for AAFP Prescribed CME credits. Determination of credit is pending.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed credit, not as Category 1.
In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), the American Academy of PAs (AAPA), American Psychological Association (APA) and Association for Social Work Boards (ASWB) to provide continuing education for the healthcare team.
American Academy of Addiction Psychiatry designates this enduring material for a maximum of 4 (four) AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been reviewed and is acceptable for up to 4 (four) Nursing Contact Hours.
Physician Assistant Designation
American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4 AAPA Category 1 CME credits. Approval is valid until 2/12/2020. PAs should only claim credit commensurate with the extent of their participation.
This course has been approved for 4 hours of pharmacy continuing education credit. The approval numbers issued are Universal Activity Numbers JA4008192-0000-19-001-H01-P (pharmacy) and JA4008192-0000-19-001-H01-T (pharmacy tech).
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 4 (four) Interprofessional Continuing Education credits for learning and change.
Method of participation in the activity: To be awarded a maximum of 4 AAPA Category 1 CME credits you must:
- Review 5 training modules (4 hours) provided in this activity.
2. Earn a passing score of 75% on each of the module’s post-tests.
3. Complete a final evaluation and follow instructions at the end of the course regarding how to retrieve your Certificate of Completion as well as your continuing credit certificate*.
*Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.
AAAP’s CE program aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, disclosure information from all series planners and speakers is provided during the planning process to ensure resolution of any identified conflicts. The following PCSS-MAT, CPD Committee and AAAP staff members have reported that they have no commercial relationships relevant to the content of this activity to disclose: Stephen Wyatt, DO, Sanchit Maruti, MD, Thomas Penders, MD, Michael Goedde, MD, Kevin Sevarino, MD, Nitigna Desai, MD, Kathryn Cates-Wessel, Justina Andonian, Miriam Giles, Seth Acton, Marie Samson and Erin Waters.
Disclosure of Unlabeled Medication Use:
Recommendations involving clinical medicine are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
American Academy of Addiction Psychiatry (AAAP) is the Data Sponsor for this training.
Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.